Eledon Pharmaceuticals, Inc. (ELDN) Stock Price & Analysis
Eledon Pharmaceuticals, Inc. (ELDN) fell 4.28% to USD 3.58 as of July 25, 2026 at 07:44 UTC, according to Nexqual real-time market data.
ELDN last closed at USD 3.74; the session ranged USD 3.5–3.76 on volume of 1,262,289 shares. Market capitalization is $276.33M, with a 52-week range of USD 1.35–4.6 (NCM). Source: Nexqual, July 25, 2026 at 07:44 UTC.
Key Statistics (as of July 25, 2026 at 07:44 UTC)
| Price | USD 3.58 |
|---|---|
| Change | ▼ 4.28% (down) |
| Previous Close | USD 3.74 |
| Open | USD 3.76 |
| Day Range | USD 3.5 – 3.76 |
| 52-Week Range | USD 1.35 – 4.6 |
| Volume | 1,262,289 shares |
| Market Cap | $276.33M |
| Exchange | NCM |
Technical Analysis (ELDN)
Nexqual's technical model rates ELDN "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.14 (neutral) |
| vs SMA50 | Below (USD 3.79) |
| MACD | -0.01 (negative) |
Analyst Ratings (ELDN)
Wall Street analysts rate ELDN "None" based on 5 analysts, with a mean price target of USD 9 (range USD 7–12), per Nexqual as of July 25, 2026 at 07:44 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 9 |
| High Target | USD 12 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ELDN)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.23 ▼ miss |
| 2025-12-31 | USD -0.1 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.21 vs est -0.25 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.23 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:44 UTC.
Financials & Fundamentals (ELDN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -72.68% |
| Debt / Equity | 0.55 |
| Current Ratio | 8.44 |
| Total Cash | $111.09M |
| Total Debt | $555,000 |
| Free Cash Flow | $-39.67M |
Source: Nexqual, July 25, 2026 at 07:44 UTC.
Financial Health Score (ELDN)
Nexqual rates Eledon Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $111M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$69M |
| Efficiency | Critical — ROE -73%, ROA -35.1% |
Ownership (ELDN)
| Insider Ownership | +1.09% |
|---|---|
| Institutional Ownership | +59.81% |
| Shares Outstanding | 77.19M |
| Float | 69.93M |
| Short % of Float | +7.16% |
Source: Nexqual, July 25, 2026 at 07:44 UTC.
Leadership (ELDN)
Eledon Pharmaceuticals, Inc. is led by David-Alexandre C. Gros (age 53), CEO & Non Independent Director, per Nexqual as of July 25, 2026 at 07:44 UTC.
| CEO & Non Independent Director | David-Alexandre C. Gros (age 53) |
|---|---|
| President, Chief Scientific Officer & Non Independent Director | Steven N. Perrin (age 59) |
| Chief Financial Officer | Paul Sean Little (age 60) |
| Vice President of Technical Operations | John Herberger |
Major Backers & Investors (ELDN)
Notable institutional backers of Eledon Pharmaceuticals, Inc. include BVF Inc., Defilade Capital Management, L.P., Ensign Peak Advisors, Inc, according to Nexqual as of July 25, 2026 at 07:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 8.15% |
| Defilade Capital Management, L.P. | 4.62% |
| Ensign Peak Advisors, Inc | 3.19% |
| Zimmer Partners, Lp | 2.43% |
| Sphera Funds Management Ltd. | 2.3% |
| Catalio Capital Management, LP | 2.12% |
| Blue Owl Capital Holdings LP | 1.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.04% |
| Vanguard Group | 8.79% |
| Geode Capital | 2.32% |
Source: Nexqual, July 25, 2026 at 07:44 UTC.
From Eledon Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
- It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
- The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential.
- It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.13 | ▼ 3.62% |
| TARA | Protara Therapeutics, Inc. | USD 4.02 | ▼ 1.47% |
| LRMR | Larimar Therapeutics, Inc. | USD 4 | ▼ 0.5% |
| RZLT | Rezolute, Inc. | USD 4.99 | ▼ 0.2% |
| ALGS | Aligos Therapeutics, Inc. | USD 4.08 | ▼ 20.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:44 UTC. This page is informational and not investment advice.